Schoretsanitis, Georgios

Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics

Pharmacovigilance and Adverse Drug ReactionsTreatment of Major Depression

Cited by 134

Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality

Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E., & Gastaldon, C. (2024) · JAMA Network Open

Pharmacovigilance and Adverse Drug ReactionsSuicide and Self-Harm Studies

Cited by 107

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone

Schoretsanitis, G., Spina, E., Hiemke, C., & de Leon, J. (2018) · Expert Review of Clinical Pharmacology

Schizophrenia research and treatmentPharmacogenetics and Drug Metabolism

Cited by 50